Sudarshan Pharma Industries has scheduled its 18th Annual General Meeting for Tuesday, September 22, 2026. The meeting will be conducted through video conferencing or other audio-visual means at 3:00 pm IST.

The primary agenda includes the adoption of audited financial statements for the fiscal year ended March 31, 2026. Shareholders will also vote on the re-appointment of Dr. Anil Ghogare as a director.

Director Re-Appointment

Dr. Anil Ghogare retires by rotation and offers himself for re-appointment as a Non-Executive Non-Independent Director. He was originally appointed to the board on November 10, 2023.

Dr. Ghogare holds a PhD in Pharmaceutical Chemistry from Mumbai University and an M.Tech from the Indian Institute of Technology, New Delhi. He possesses 37 years of experience in fermentation technology and serves as a regulatory consultant for pharmaceutical plant design and technology transfers.

Meeting Logistics

The company will provide remote e-voting facilities through National Securities Depository Limited. The voting period begins on Saturday, September 19, 2026, at 9:00 am and ends on Monday, September 21, 2026, at 5:00 pm.

The record date for determining voting eligibility is Tuesday, September 15, 2026. Members can attend the meeting via video conferencing starting 15 minutes before the scheduled time. Proxy appointments are not available for this meeting.

What the Numbers Show

The disclosure notes that Dr. Ghogare drew nil remuneration in the last reported period and holds no shareholding in the company. This aligns with his role as a non-executive director focused on technical advisory rather than operational management.

Sudarshan Pharma Industries promoters Hemal V Mehta and Sachin V Mehta pledged a combined 1.33 crore equity shares on August 25, 2026. The encumbrance was created in favor of Satin Finserv Limited as security for loans taken by third parties.

Pledge Details

Both promoters disclosed the creation of pledges under Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The disclosures were filed with BSE Limited on August 26, 2026.

Hemal V Mehta holds 6,85,21,020 shares, representing 26.93% of the total share capital. Sachin V Mehta holds 7,07,05,470 shares, accounting for 27.79% of the total share capital.

What the Numbers Show

The new pledge increases the total encumbered stake for both promoters to 5.21% of the company’s total share capital. This indicates that roughly one-fifth of each promoter’s individual holding is now pledged, as Hemal V Mehta’s encumbered portion rises from 2.59% to 5.21%, and Sachin V Mehta’s follows the identical trajectory.